TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Foghorn Therapeutics ( (FHTX) ).
Foghorn Therapeutics has made significant advancements in its drug development programs, particularly in chromatin biology and protein degradation. The company is progressing multiple high-value assets into clinical trials, including FHD-909, a selective SMARCA2 inhibitor, and anticipates updates on the ARID1B program in 2025, positioning itself strongly in the oncology therapeutics market.
More about Foghorn Therapeutics
Foghorn Therapeutics operates in the biopharmaceutical industry, focusing on precision therapeutics for chromatin biology. The company develops first-in-class treatments targeting chromatin regulation, which is implicated in numerous tumors, and leverages its Gene Traffic Control Platform® to create innovative therapeutic candidates.
YTD Price Performance: -8.71%
Average Trading Volume: 152,858
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $233M
Learn more about FHTX stock on TipRanks’ Stock Analysis page.